Quality of life and cost of strategies of two chemotherapy lines in metastatic colorectal cancer: results of the FFCD 2000-05 trial
| Affiliation auteurs | !!!! Error affiliation !!!! |
| Titre | Quality of life and cost of strategies of two chemotherapy lines in metastatic colorectal cancer: results of the FFCD 2000-05 trial |
| Type de publication | Journal Article |
| Year of Publication | 2019 |
| Auteurs | Lacas B, Bouche O, Etienne P-L, Gasmi M, Texereau P, Gargot D, Lombard-Bohas C, Azzedine A, Denis B, Geoffroy P, Auby D, Michel P, Pignon J-P, Lepage C, Ducreux M, Borget I, Collaborative FFCD2000-05 Tr |
| Journal | EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH |
| Volume | 19 |
| Pagination | 601-608 |
| Date Published | SEP 3 |
| Type of Article | Article |
| ISSN | 1473-7167 |
| Mots-clés | cost, Irinotecan, metastatic colorectal cancer, oxaliplatin, Quality of life, Randomised trial |
| Résumé | {Objectives: This study compared the cost and quality of life (QoL) of 407 advanced colorectal cancer patients, randomly assigned to receive LV5FU2 followed by FOLFOX6 (sequential strategy) or FOLFOX6 followed by FOLFIRI (combination strategy). Methods: Costs were compared from the French health insurance perspective, until the end of the second line of treatment. Consumed resources, collected during the trial, included medicines, hospitalizations, examinations, and transportation. Valuations were made using 2009 and 2016 tariffs. QoL was assessed using the QLQ-C30 questionnaire and clinically significant variations were searched. Results: In 2009, the mean cost per patient was significantly lower for the sequential strategy compared to the combination strategy (18,061euro and 23,119euro |
| DOI | 10.1080/14737167.2019.1580573 |